Although GLP-1 RAs do not affect warfarin pharmacokinetics, their appetite-reducing effects may decrease vitamin K intake and increase International Normalized Ratio (INR) variability
Patients must focus on nutrition, exercise, and overall wellness to achieve long-term success
Obesity Management: The STEP UP trial demonstrated significant weight loss with semaglutide 7.2mg, with participants losing 20.7% of their body weight after 72 weeks, compared to 17.5% with the 2.4mg dose and only 2.4% with placebo
Most people tolerate the split schedule without issue
Working Im interested In getting your program to loose weight for my health
NICE recommends GLP-1 receptor agonists for people with a BMI 35 kg/m (or lower in certain ethnic groups), or when obesity-related complications are present, or when insulin would have significant occupational implications